Market Research Logo

Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Global Overactive Bladder Therapeutics Market: About this market

Technavio’s overactive bladder (OAB) therapeutics market analysis considers sales from anticholinergics. Beta-3 adrenergic agonists, and other OAB therapeutics. Our analysis also considers the sales of overactive bladder therapeutics in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing availability of branded drugs and rise in popularity of combination therapy will play a significant role in the anticholinergics segment to maintain its market position. Also, our global overactive bladder therapeutics market report looks at factors such as the increasing number of drug approvals, the advent of combination therapy, and strategic alliance. However, extensive use devices to treat OAB, side effects associated with OAB, and rising patent litigations may hamper the growth of the overactive bladder therapeutics industry over the forecast period.

Global Overactive Bladder Therapeutics Market: Overview

The advent of combination therapy

The launch of combination therapy offers patients an efficacious pharmacological regime which requires shorter duration for treatment and reduces the overall cost associated with medication treatment. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. This advent of combination therapy will lead to the expansion of the global overactive bladder therapeutics market at a CAGR of almost 2% during the forecast period.

The advent of gene therapy

The treatment therapy available for OAB involves the use of small molecules, which helps in the relaxation of smooth muscles in the urinary bladder to control the emptying of the bladder. The medication therapy, which is used exerts its pharmacological effect by suppressing the overactivity of the detrusor muscle. The drugs used in the therapy are associated with certain side effects like dry mouth, constipation, blurred vision, and cognitive impairment. Thus, there is a need for the development of biological drugs targeting the gene and consequently improving bladder functioning. The ongoing research in this area is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global overactive bladder therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global overactive bladder therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position. This report provides a detailed analysis of several leading overactive bladder therapeutics manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Camber Pharmaceuticals Inc., Endo International Plc., KYORIN Holdings Inc., Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Vendors: Key offerings
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Pipeline landscape
    • Table Some key clinical trials in global OAB therapeutics market
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Anticholinergics - Market size and forecast 2018-2023
      • Table Anticholinergics - Market size and forecast 2018-2023 ($ millions)
      • Table Anticholinergics - Year-over-year growth 2019-2023 (%)
    • Beta-3 adrenergic agonists - Market size and forecast 2018- 2023
      • Table Beta-3 adrenergic agonists - Market size and forecast 2018-2023 ($ millions)
      • Table Beta-3 adrenergic agonists - Year-over-year growth 2019-2023 (%)
    • Other OAB therapeutics - Market size and forecast 2018- 2023
      • Table Other OAB therapeutics - Market size and forecast 2018-2023 ($ millions)
      • Table Other OAB therapeutics - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Advent of gene therapy
    • Rising risk factors of OAB
    • Growing geriatric population
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AbbVie Inc.
      • Table AbbVie Inc. - Vendor overview
      • Table AbbVie Inc. - Business segments
      • Table AbbVie Inc. - Organizational developments
      • Table AbbVie Inc. - Geographic focus
      • Table AbbVie Inc. - Key offerings
      • Table AbbVie Inc. - Key customers
    • Astellas Pharma Inc.
      • Table Astellas Pharma Inc. - Vendor overview
      • Table Astellas Pharma Inc. - Business segments
      • Table Astellas Pharma Inc. - Organizational developments
      • Table Astellas Pharma Inc. - Geographic focus
      • Table Astellas Pharma Inc. - Key offerings
      • Table Astellas Pharma Inc. - Key customers
    • Camber Pharmaceuticals Inc.
      • Table Camber Pharmaceuticals Inc. - Vendor overview
      • Table Camber Pharmaceuticals Inc. - Business segments
      • Table Camber Pharmaceuticals Inc. - Organizational developments
      • Table Camber Pharmaceuticals Inc. - Key offerings
      • Table Camber Pharmaceuticals Inc. - Key customers
    • Endo International Plc
      • Table Endo International Plc - Vendor overview
      • Table Endo International Plc - Business segments
      • Table Endo International Plc - Organizational developments
      • Table Endo International Plc - Geographic focus
      • Table Endo International Plc - Segment focus
      • Table Endo International Plc - Key offerings
      • Table Endo International Plc - Key customers
    • KYORIN Holdings Inc.
      • Table KYORIN Holdings Inc. - Vendor overview
      • Table KYORIN Holdings Inc. - Business segments
      • Table KYORIN Holdings Inc. - Organizational developments
      • Table KYORIN Holdings Inc. - Geographic focus
      • Table KYORIN Holdings Inc. - Segment focus
      • Table KYORIN Holdings Inc. - Key offerings
      • Table KYORIN Holdings Inc. - Key customers
    • Merck & Co. Inc.
      • Table Merck & Co. Inc. - Vendor overview
      • Table Merck & Co. Inc. - Business segments
      • Table Merck & Co. Inc. - Organizational developments
      • Table Merck & Co. Inc. - Geographic focus
      • Table Merck & Co. Inc. - Segment focus
      • Table Merck & Co. Inc. - Key offerings
      • Table Merck & Co. Inc. - Key customers
    • Mylan NV
      • Table Mylan NV - Vendor overview
      • Table Mylan NV - Product segments
      • Table Mylan NV - Organizational developments
      • Table Mylan NV - Geographic focus
      • Table Mylan NV - Segment focus
      • Table Mylan NV - Key offerings
      • Table Mylan NV - Key customers
    • Ono Pharmaceutical Co. Ltd.
      • Table Ono Pharmaceutical Co. Ltd. - Vendor overview
      • Table Ono Pharmaceutical Co. Ltd. - Business segments
      • Table Ono Pharmaceutical Co. Ltd. - Organizational developments
      • Table Ono Pharmaceutical Co. Ltd. - Geographic focus
      • Table Ono Pharmaceutical Co. Ltd. - Key offerings
      • Table Ono Pharmaceutical Co. Ltd. - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
    • Teva Pharmaceutical Industries Ltd.
      • Table Teva Pharmaceutical Industries Ltd. - Vendor overview
      • Table Teva Pharmaceutical Industries Ltd. - Business segments
      • Table Teva Pharmaceutical Industries Ltd. - Organizational developments
      • Table Teva Pharmaceutical Industries Ltd. - Segment focus
      • Table Teva Pharmaceutical Industries Ltd. - Key offerings
      • Table Teva Pharmaceutical Industries Ltd. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report